{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-24-000073","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.749372+00:00","generated_at":"2026-05-31T11:11:09.782263+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Barinthus Bio Q2 2024 net loss $16.9M; prioritizes HBV and celiac programs; CMO hired","bullets":["Net loss of $16.9M ($0.43 per share) compared to $15.5M ($0.40) in Q1 2024.","Cash $117.8M at June 30, 2024, down from $130.0M at March 31, 2024; runway into Q2 2026.","Pipeline prioritized: VTP-300 (HBV) and VTP-1000 (celiac disease); workforce reduction announced.","Dr. Leon Hooftman appointed Chief Medical Officer effective June 3, 2024.","Upcoming milestones: VTP-1000 Phase 1 first patient dosing in Q3 2024; HBV data updates in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-24-000073","json":"https://secwatch.observer/filing/0001828185-24-000073.json","markdown":"https://secwatch.observer/filing/0001828185-24-000073.md","text":"https://secwatch.observer/filing/0001828185-24-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000073/0001828185-24-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000073/brns-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:11:09.782263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}